Roy S. Herbst, MD, PhD, on What Multidisciplinary Providers Should Know About KEYNOTE-010


The KEYNOTE-010 study evaluated the use of either pembrolizumab or docetaxel in patients with previously treated, PD-L1–positive advanced non–small cell lung cancer.

With over 5 years of follow-up, pembrolizumab (Keytruda) continued to demonstrate clinically meaningful improvements in both overall survival (OS) and progression-free survival (PFS) versus docetaxel among patients with previously treated, advanced non–small cell lung cancer with a PD-L1 tumor proportion score (TPS) of at least 1%, according to updated results from the KEYNOTE-010 study (NCT01905657) presented at the IASLC 2020 World Conference on Lung Cancer.

In an interview with CancerNetwork®, Roy S. Herbst, MD, PhD, of the Yale Cancer Center and Smilow Cancer Hospital, explained what multidisciplinary care teams can take away from this research.


Lung cancer is treated in a multidisciplinary setting; and certainly, if someone is treated in a metastatic setting, we should think about therapy as early as possible. But also, these drugs can now be used in the adjuvant setting. We already know from the PACIFIC trial (NCT02125461) that durvalumab improves survival after chemoradiation. And I’m confident that we’ll see some interesting results soon from some of the Agilent trials in stage I to III disease.


Herbst R, Garon E, Kim D, et al. 5-year survival update from KEYNOTE-010: pembrolizumab versus docetaxel in previously treated, PD-L1–positive advanced NSCLC. Presented at the IASLC 2020 World Conference on Lung Cancer. Abstract FP13.01.

Related Videos
Common adverse effects following treatment with lenvatinib plus pembrolizumab in the phase 3 CLEAR study include diarrhea, hypertension, and fatigue, according to Thomas E. Hutson, DO, PharmD, FACP.
Lenvatinib in combination with pembrolizumab appears to raise no new safety signals in patients with advanced clear cell renal cell carcinoma after 4 years of follow-up in the phase 3 CLEAR study.
According to Thomas E. Hutson, DO, PharmD, FACP, 4-year follow-up data from the phase 3 CLEAR study confirm the maintained benefits of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Rana R. McKay, MD discusses presentations of interest that were presented at the 2023 Kidney Cancer Research Summit, including a discussion on how PET imaging may identify which patients with renal cell carcinoma may respond to immunotherapy.
A better understanding of tumor biology may be necessary for identifying novel non-immunotherapy–based therapeutic strategies for patients with renal cell carcinoma, according to Rana R. McKay, MD.
Probiotics and other agents targeting fatty acid oxidation are also under evaluation as treatment options for patients with renal cell carcinoma, according to Rana R. McKay, MD.
Other angiogenic agents are also under investigation in renal cell carcinoma, according to Rana McKay, MD, who indicates it will be interesting to see how they compare with belzutifan.
Expert on NSCLC
Related Content